Meeting Banner
Abstract #3471

Role of Functional Diffusion Maps as an Imaging Biomarker for Treatment Response Assessment in Recurrent/progressive Malignant Gliomas Treated with Bevacizumab

Rajan Jain1, Shehanaz Ellika, Lisa Scarpace, Roy Torcuator, Lonni Schultz, David Hearshen, Tom Mikkelsen

1Henry Ford Health System, Detroit, MI, USA

Imaging criteria of measuring tumor area/volume only, to assess treatment response may not be sufficient in patients on anti-angiogenic therapy and other functional imaging biomarkers such as ADC values can be helpful in treatment response assessment of these patients. In the present study, recurrent/progressive malignant gliomas treated with bevacizumab, CELADC (contrast enhancing lesion ADC) and NELADC (non-enhancing lesion ADC) showed a progressive increase in responders suggesting treatment response, probable tumor cell death and decreasing tumor cell density. Non-responders showed a progressive decrease of CELADC and NELADC suggesting increase of tumor cell density, hyper cellular infiltrative tumor growth and treatment failure.